(Hypertension. 1997;29:744-750.)
© 1997 American Heart Association, Inc.
Articles |
Effect of Calcium Channel or ß-Blockade on the Progression of Diabetic Nephropathy in African Americans
the Department of Medicine, Division of Nephrology, Ochsner Clinic, New Orleans, La (G.L.B., J.B.C., N.V., R.S.), and Rush University Hypertension Center, Rush-Presbyterian/St Luke's Medical Center, Chicago, Ill (G.L.B., A.M.).
Correspondence to George L. Bakris, MD, FACP, Rush University Hypertension Center, Rush-Presbyterian/St Luke's Medical Center, 1725 W Harrison, Suite 117, Chicago, IL 60612. E-mail gbakris@rpslmc.edu
ß-Blockers are known to slow the progression of diabetic nephropathy by lowering arterial pressure. Moreover, in individuals with diabetic nephropathy, antihypertensive agents that provide sustained reductions in proteinuria slow the rate of decline in renal function compared with agents without this antiproteinuric effect. To examine whether differential effects on proteinuria affect the progression of diabetic nephropathy, we conducted a randomized study that compared the effects of a heart rate–lowering calcium channel blocker, sustained-release verapamil, with those of a ß-blocker, atenolol, on the progression of diabetic renal disease. The primary end point of the study was a change in creatinine clearance slope. Thirty-four African Americans with the following inclusion criteria were randomized to one of the two groups: serum creatinine greater than 1.4 mg/dL, proteinuria greater than 1500 mg/d, longer than a 5-year history of both non–insulin-dependent diabetes mellitus and hypertension, and exclusion of other renal diseases. Goal blood pressure was less than 140/90 mm Hg. All subjects received loop diuretics as second line agents to help achieve the blood pressure goal. Twenty-four-hour urinary protein and sodium excretions as well as creatinine clearance were measured at 6-month intervals. Blood pressure was measured every 3 months. After a mean follow-up of 54±6 months, the calcium channel blocker group demonstrated both a slower rate of decline in creatinine clearance (-1.7±0.9 versus -3.7±1.4 mL/min per year per 1.73 m2, P<.01) and a greater reduction in proteinuria compared with the atenolol group. Additionally, a greater proportion of the atenolol group had a 50% or more increase in serum creatinine compared with the verapamil group (32±9% versus 16±7%, P<.05). These between-group differences could not be explained by differences in blood pressure control. These data support the concept that antihypertensive agents that persistently maintain reductions in both arterial pressure and proteinuria slow the progression of diabetic renal disease in African Americans to a greater extent than those agents without these effects.
Key Words: blacks • diabetic nephropathies • calcium channel blockers • verapamil • atenolol • adrenergic beta-antagonists
This article has been cited by other articles:
 |
|
 |
|
  J. K Kirk, R. A Bell, A. G Bertoni, T. A Arcury, S. A Quandt, D. C Goff Jr., and K M V. Narayan Ethnic Disparities: Control of Glycemia, Blood Pressure, and LDL Cholesterol Among US Adults with Type 2 Diabetes Ann. Pharmacother., September 1, 2005; 39(9): 1489 - 1501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Abbott, E. Basta, and G. L. Bakris Blood Pressure Control and Nephroprotection in Diabetes J. Clin. Pharmacol., April 1, 2004; 44(4): 431 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. T. Yu Progression of Chronic Renal Failure Arch Intern Med, June 23, 2003; 163(12): 1417 - 1429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. R. Loon Diabetic Kidney Disease: Preventing Dialysis and Transplantation Clin. Diabetes, April 1, 2003; 21(2): 55 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Douglas, G. L. Bakris, M. Epstein, K. C. Ferdinand, C. Ferrario, J. M. Flack, K. A. Jamerson, W. E. Jones, J. Haywood, R. Maxey, et al. Management of High Blood Pressure in African Americans: Consensus Statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks Arch Intern Med, March 10, 2003; 163(5): 525 - 541. [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Wright Jr, G. Bakris, T. Greene, L. Y. Agodoa, L. J. Appel, J. Charleston, D. Cheek, J. G. Douglas-Baltimore, J. Gassman, R. Glassock, et al. Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney Disease: Results From the AASK Trial JAMA, November 20, 2002; 288(19): 2421 - 2431. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Swales and B. Williams Review: Calcium channel blockade in combination with angiotensin-converting enzyme inhibition or angiotensin II (AT1-receptor) antagonism in hypertensive diabetics and patients with renal disease and hypertension Journal of Renin-Angiotensin-Aldosterone System, June 1, 2002; 3(2): 79 - 89. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Arauz-Pacheco, M. A. Parrott, and P. Raskin The Treatment of Hypertension in Adult Patients With Diabetes Diabetes Care, January 1, 2002; 25(1): 134 - 147. [Full Text] [PDF]
|
|
|
|
|
|
G. L. Bakris A Practical Approach to Achieving Recommended Blood Pressure Goals in Diabetic Patients Arch Intern Med, December 10, 2001; 161(22): 2661 - 2667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Y. Agodoa, L. Appel, G. L. Bakris, G. Beck, J. Bourgoignie, J. P. Briggs, J. Charleston, D. Cheek, W. Cleveland, J. G. Douglas, et al. Effect of Ramipril vs Amlodipine on Renal Outcomes in Hypertensive Nephrosclerosis: A Randomized Controlled Trial JAMA, June 6, 2001; 285(21): 2719 - 2728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Nielsen and A. Flyvbjerg Calcium channel blockers - the effect on renal changes in clinical and experimental diabetes: an overview Nephrol. Dial. Transplant., May 1, 2000; 15(5): 581 - 585. [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Abernethy and J. B. Schwartz Calcium-Antagonist Drugs N. Engl. J. Med., November 4, 1999; 341(19): 1447 - 1457. [Full Text] [PDF]
|
|
|
|
 |
|
 C.R. Gibbs, D.G. Beevers, and G.Y.H. Lip The management of hypertensive disease in Black patients QJM, April 1, 1999; 92(4): 187 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hemmelder, D. de Zeeuw, and P. de Jong Antiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease Nephrol. Dial. Transplant., January 1, 1999; 14(1): 98 - 104. [Abstract] [PDF]
|
|